A Modular, Open-Label, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics (pks) and Anti-Tumour Activity of a First-in-class (FIC) Specific Dutpase Inhibitor CV6-168 Combined with Anti-Cancer Treatments in Patients (pts) with Advanced Malignancies.